AIM
REGN icon

Artemis Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Artemis Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-271
Closed -$122K – 277
2015
Q1 		$122K Sell
271
-4,369
-94% -$1.85M ﹤0.01% 239
2014
Q4 		$1.9M Buy
+4,640
New +$1.82M 0.07% 173

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Artemis Investment Management's REGN Position: Q2 2015 in Review

Artemis Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2015, closing a stake of 271 shares — an estimated $122K sold.

Artemis Investment Management first reported a position in REGN in Q4 2014 and held it in 2 quarters. The position peaked at $1.9M in Q4 2014. 540 funds tracked by Wall St. Rank hold REGN as of Q2 2015.

  • Artemis Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Artemis Investment Management sold 271 Regeneron Pharmaceuticals shares in Q2 2015, an estimated $122K.
  • Artemis Investment Management first reported a position in Regeneron Pharmaceuticals in Q4 2014 and held it in 2 quarters.
  • Artemis Investment Management's Regeneron Pharmaceuticals position peaked at $1.9M in Q4 2014.
  • 540 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2015.

Based on Artemis Investment Management's 13F filing for Q2 2015, filed 29 Jul 2015.